PRESS RELEASE published on 02/25/2025 at 22:01, 9 months 7 days ago DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress DBV Technologies to participate in AAAAI/WAO Joint Congress to present long-term efficacy results of epicutaneous immunotherapy with VIASKIN peanut patch in peanut-allergic children aged 4-11 years, showcasing treatment benefits and high compliance rates DBV Technologies Epicutaneous Immunotherapy Viaskin Peanut Patch AAAAI/WAO Joint Congress PEPITES Study
BRIEF published on 01/13/2025 at 22:10, 10 months 22 days ago DBV Technologies Half-Yearly Liquidity Statement Liquidity Contract ODDO BHF Stock Market Transactions DBV Technologies VIASKIN®
PRESS RELEASE published on 01/13/2025 at 22:05, 10 months 22 days ago Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies issues Half-Year Report on liquidity contract with ODDO BHF, revealing assets in the account and transaction details Liquidity Contract Half-year Report Biopharmaceutical Company ODDO BHF DBV Technologies
BRIEF published on 12/02/2024 at 22:35, 1 year ago DBV Technologies: Voting rights and shares as of November 30, 2024 Share Capital Voting Rights Actions DBV Technologies NYSE Euronext Paris
PRESS RELEASE published on 12/02/2024 at 22:30, 1 year ago Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2024 Company provides update on total voting rights and shares as of November 30, 2024 in compliance with AMF regulations Shares Total Voting Rights AMF Regulations NYSE Euronext Paris November 30 2024
BRIEF published on 11/20/2024 at 15:33, 1 year ago Braidwell LP Crosses Thresholds at DBV Technologies Actions Investment Crossing Thresholds DBV Technologies Braidwell LP
BRIEF published on 11/06/2024 at 22:35, 1 year ago DBV Technologies Facing Financial Uncertainties in Q3 2024 Financial Results Cash Flow Net Loss Q3 2024 DBV Technologies
PRESS RELEASE published on 11/06/2024 at 22:30, 1 year ago DBV Technologies Reports Third Quarter 2024 Financial Results DBV Technologies reports Q3 2024 financial results, with $46.4 million cash balance. Approves quarterly financial statements. Faces challenges in securing future financing Financial Results Financing Clinical Trials Cash Balance DBV Technologies
BRIEF published on 10/31/2024 at 09:05, 1 year 1 month ago Braidwell LP Crosses Thresholds in DBV Technologies Warrants Actions DBV Technologies Participation Threshold Braidwell LP
BRIEF published on 10/22/2024 at 22:50, 1 year 1 month ago DBV's Viaskin Peanut Patch Secures Regulatory Progress in US and EU FDA Approval DBV Technologies Viaskin Peanut Regulatory Update EMA Guidance
Published on 12/05/2025 at 02:35, 11 hours 19 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 12 hours 54 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 14 hours 49 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 14 hours 54 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 13:45, 9 minutes ago BingX Introduces Recurring Buy to Help Users Ride Out Crypto Market Swings
Published on 12/05/2025 at 13:00, 54 minutes ago Zentra Group plc: Posting of Notice of Annual General Meeting
Published on 12/05/2025 at 13:00, 54 minutes ago Form 8.3 - Zürcher Kantonalbank: Cicor Technologies Ltd.
Published on 12/05/2025 at 12:05, 1 hour 49 minutes ago Cango Inc. Announces November 2025 Bitcoin Production and Mining Operations Update
Published on 12/05/2025 at 12:00, 1 hour 54 minutes ago CGTN：Strengthening cultural ties: Peng Liyuan, Brigitte Macron visit Beijing People's Art Theatre
Published on 12/05/2025 at 08:45, 5 hours 9 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 19 hours 54 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 20 hours 9 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 20 hours 10 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 6 hours ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
